Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 5 participants, all of whom completed the study. Every participant received the same treatment combination: bevacizumab, fludarabine, and melphalan. The trial was measuring "progression-free survival" in the first 100 days after a transplant — in plain terms, this means it was tracking how many participants had no signs of their disease getting worse and did not die during that period. Participants were then followed up every three months for the first year. The reported data shows that no numerical results were submitted for the primary outcome measure (progression-free survival). While the trial recorded that all 5 participants started and completed the study, the actual measurement figures for how many participants experienced no disease progression or death during the 100-day window were not reported in the data submitted to ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are between 18 and 65 years old
- You have one of the following: metastatic breast cancer that responded to treatment (or bone-only spread that stayed stable), advanced low-grade ovarian cancer, or advanced high-grade ovarian cancer that responded to treatment before transplant
- You are in good general health and able to carry out daily activities with little or no limitation (confirm with trial site)
- You have a matching donor — either a family member or unrelated donor — who is willing and able to donate stem cells or bone marrow
- You have had at least one prior chemotherapy treatment for breast or ovarian cancer (or two prior treatments including targeted therapy for kidney cancer)
- Your heart is pumping well enough, with a pumping strength of at least 45% (or you can get clearance from a heart doctor if slightly below this)
- Your lungs are working at least 50% as well as expected for someone your age and size (or you can get clearance from a lung doctor if slightly below this)
- Your kidneys are functioning adequately, based on blood test results
- Your liver is functioning adequately, based on blood test results
- You are willing and able to sign a consent form agreeing to take part
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have previously had an allogeneic (donor) stem cell transplant
- You have another serious illness that severely limits how long you are expected to live
- You currently have a significant active infection
- You have HIV
- You have chronic active hepatitis (ongoing liver inflammation caused by a virus)
- You are pregnant or breastfeeding
- You have had cancer spread to multiple areas of the brain — or a single brain metastasis that has not been fully treated, or where imaging shows it returned or caused swelling within the last 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression-free Survival (PFS)
Other options
Data last synced from ClinicalTrials.gov: 17 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.